Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium
Business Wire•19/11/2026•07:30 ET
1
Key Highlights
- ➤Tempus (TEM) to present 16 breast cancer abstracts at 2026 SABCS
- ➤Late-breaking study uses oFM trained on data from more than 1.6 million cancer patients
- ➤oFM analyzes longitudinal clinical and molecular data for metastatic breast cancer treatment benefits
- ➤Presentations cover AI-guided treatment selection, liquid biopsy, and real-world treatment outcomes
Expert Statements
Ezra Cohen, Chief Medical Officer of Oncology at Tempus
“As our understanding of breast cancer advances and treatment options expand, having the right information to guide care is more important than ever”
Ezra Cohen, Chief Medical Officer of Oncology at Tempus
“By combining advanced molecular testing with our extensive multimodal database and AI, we are uncovering insights that go beyond conventional approaches to understanding cancer biology, treatment response and resistance”
Ezra Cohen, Chief Medical Officer of Oncology at Tempus
“This research demonstrates the potential of our integrated platform to inform more personalized treatment decisions and advance cancer care”
Tempus to Present 16 Abstracts at the 2026 San Antonio Breast Cancer Symposium
Presentations include late-breaking data demonstrating the potential of AI to inform breast cancer treatment decisions
Get started
Create a free account to read the full story.
